Abstract
Inflammatory bowel diseases (IBD), namely Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammation within the gastrointestinal tract. IBD patient conditions and treatments, such as with immunosuppressants, may result in a higher risk of viral and bacterial infection and more severe outcomes of infections. The effect of the clinical and demographic factors on the prognosis of COVID-19 among IBD patients is still a significant area of investigation. The lack of available data on a large set of COVID-19 infected IBD patients has hindered progress. To circumvent this lack of large patient data, we present a random sampling approach to generate clinical COVID-19 outcomes (outpatient management, hospitalized and recovered, and hospitalized and deceased) on 20,000 IBD patients modeled on reported summary statistics obtained from the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD), an international database to monitor and report on outcomes of COVID-19 occurring in IBD patients. We apply machine learning approaches to perform a comprehensive analysis of the primary and secondary covariates to predict COVID-19 outcome in IBD patients. Our analysis reveals that age, medication usage and the number of comorbidities are the primary covariates, while IBD severity, smoking history, gender and IBD subtype (CD or UC) are key secondary features. In particular, elderly male patients with ulcerative colitis, several preexisting conditions, and who smoke comprise a highly vulnerable IBD population. Moreover, treatment with 5-ASAs (sulfasalazine/mesalamine) shows a high association with COVID-19/IBD mortality. Supervised machine learning that considers age, number of comorbidities and medication usage can predict COVID-19/IBD outcomes with approximately 70% accuracy. We explore the challenge of drawing demographic inferences from existing COVID-19/IBD data. Overall, there are fewer IBD case reports from US states with poor health ranking hindering these analyses. Generation of patient characteristics based on known summary statistics allows for increased power to detect IBD factors leading to variable COVID-19 outcomes. There is under-reporting of COVID-19 in IBD patients from US states with poor health ranking, underpinning the perils of using the repository to derive demographic information.
Highlights
Coronavirus Infectious Disease 2019 (COVID-19) is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
This international, pediatric and adult database based on collaborative participation (1) monitors and reports on outcomes of COVID-19 occurring in Inflammatory bowel disease (IBD) patients and (2) provides the IBD community with updates on affected numbers based on demography
We carried out a comprehensive analysis of the clinical factors affecting the COVID-19 outcomes of IBD patients using machine learning methods
Summary
Coronavirus Infectious Disease 2019 (COVID-19) is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used supervised and unsupervised machine learning-based statistical methods to model large amounts of IBD patient data Using these data, we present a comprehensive study of the effects of features such as gender, age, medication usage, IBD subtype (CD or UC), disease severity and demographics of IBD patients, and the accuracy of using them to predict COVID-19 outcomes. We present a comprehensive study of the effects of features such as gender, age, medication usage, IBD subtype (CD or UC), disease severity and demographics of IBD patients, and the accuracy of using them to predict COVID-19 outcomes Our analysis captures both primary and secondary factors contributing to mortality in Crohn’s disease as well as ulcerative colitis patients due to COVID-19. We explore the challenges of inferring demographics from the existing COVID-19/IBD dataset
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.